Why carry out this study?

Lenvatinib is the most commonly prescribed first-line treatment for radioactive iodine-refractory differentiated thyroid cancer (RAI-r DTC).

This was the first and largest study to explore real-world clinical outcomes of first-line lenvatinib in addition to treatment patterns and outcomes in second-line post-lenvatinib among patients with RAI-r DTC in the USA.

What was learned from the study?

Real-world clinical outcomes of first-line lenvatinib therapy were similar to that observed in the randomized controlled trial.

Patients derived a clinical benefit from multiple different agents and classes of agents in second-line after first-line lenvatinib.